continu lymphokine-activ killer cell advanc cancer nation biotherapi studi group trial multicent phase II trial continuous-infus recombin lymphokine-activ killer lak cell patient advanc cancer measur diseas good perform level treatment continu infus day rest day leukapheresi cell vitro augment cellular cytotox day infus reinfus lak cell success day therapi week patient male median age year eighty-two percent oncolog unit intens care unit patient month therapi renal cell carcinoma respons rate patient median surviv month melanoma respons rate patient median surviv month histolog respons rate patient median surviv month respond asymptomat therapi trial feasibl continu lak cell intens care unit environ antitumor activ melanoma similar multicent trial bolu lak cell activ renal cell cancer 